Grants Funded

Pilot Grant Awards | Drug Discovery Grants Awarded | Postdoctoral Fellow Awards

Pilot Grant Awards

2013 Emily Rogalski Northwestern University Internet-based speech therapy: Improving quality of life and access to care
2011 Fenghua Hu, Cornell University Signaling mechanisms of progranulin
2010 Stephanie Cosentino Columbia University Early indicators and modifiers of age of onset of FTD
2010 Stephen Strittmatter Yale University Imaging the Role of Progranulin Interaction with Sortilin in Frontotemporal Lobar Degeneration
2009 John Van Swieten, Erasmus Medical Center Rotterdam Resting-State functional MRI in presymptomatic mutation carriers of MAPT or PGRN mutation
2008 Mark A. Gluck Rutgers University Insensitivity to Negative (Penalizing) Feedback for Inappropriate Behaviors in FTD Linked to Orbito-Frontal Dysfunction
2008 Rosa Rademakers Mayo Clinic-Jacksonville MicroRNA dysregulation in frontotemporal lobar degeneration
2007 Marc Cruts University of Antwerp Gene identification in a novel Mendelian FTLD-MND locus
2007 Paul Taylor University of Pennsylvania Assessing the molecular genetics of TDP-43-related neurodegeneration using a Drosophila model
2006 Blair Leavitt & Ian Mackenzie University of British Colombia Generation of a Mouse Model of Familial FTD caused by Progranulin Mutations
2005 Eileen Bigio, MD Northwestern University To study the ubiquitinated proteins that are found in the “inclusions” that characterize brain cells in FTLD-MND

Drug Discovery Grants Awarded

2013 Jeffrey Rothstein Johns Hopkins University, School of Medicine FTD C9ORF72 Based Biomarkers for Antisense-based Drug Discovery Validation

 

2013 Donald Lo Center for Drug Discovery and Department of Neurobiology

 

Brain slice screen for microRNA-targeted drug lead candidates for tau-associated FTD

 

2012 Jeffrey Rothstein Johns Hopkins University, School of Medicine Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients

 

2012 Nigel Cairns Washington University, St. Louis

 

Restoring progranulin in frontotemporal disease

 

2012 W. Huang Yu

 

Columbia University Medical Center

 

Development of small molecule enhancers of autophagy for the clearance of protein aggregates and treatment of FTD

 

2011 Adam Boxer University of California, San Francisco Biomarker Optimization for Progranulin Trials

 

2011 William Seeley University of California, San Francisco Dynamic disease-monitoring network biomarkers for tracking frontotemporal dementia

 

2011 Charlotte Teunissen

 

VU University Medical Center

 

Identification of novel discriminatory CSF biomarkers for different FTD subtypes by proteomics

 

2010 William Hu Emory University School of Medicine

 

CSF Biomarkers of FTLD-TDP and FTLD-Tau — A Multi-Center Study

 

2010 Allen Roses

 

Duke University Fine-mapping and characterization of genetic biomarkers that facilitate the acceleration of drug discovery for frontotemporal dementias

 

2010 Marcel M. Verbeek

 

Stichting Katholieke Universiteit

 

TDP-43 and tau as cerebrospinal fluid biomarkers to discriminate frontotemporal dementia subtypes

 

2010 Victor Villemagne

 

Austin Health

 

[18F]-THK523, a novel in vivo tau imaging agent

 

2009 Einar M. Sigurdsson

 

New York University School of Medicine

 

Passive Immunotherapy for Frontotemporal Dementia

 

2009 Philip Van Damme

 

VIB

 

Drug Discovery for Progranulin-Mediated Frontotemporal Lobar Degeneration

 

2009 W. Huang Yu

 

Columbia University Tau Clearance by Autophagy

 

2008 Adam Boxer University of California San Francisco A Pilot Clinical Trial of NAP (AL-108) for Corticobasal Degeneration and Frontotemporal Lobar Degeneration with Predicted Corticobasal Degeneration Pathology

 

2008 Gabriela Chiosis

 

Memorial Sloan-Kettering Cancer Center

 

Hsp90 inhibitors in tauopathies: in vivo pre-clinical development

 

2008 Virginia Y.-M. Lee University of Pennsylvania School of Medicine Frontotemporal Lobar Degeneration (FTLD) Biomarker Assays

 

2007 Ben Bahr University of North Carolina at Pembroke

 

In vitro testing of new lysosomal modulatory drugs for reducing tau aggregates in a hippocampal slice model

 

2007 Einar M. Sigurdsson

 

NYU School of Medicine

 

Clearance of Pathological Tau Conformers
2007 Tara Spires-Jones

 

Massachusetts General Hospital

 

Sirtuins as modifiers of neurodegeneration in a mouse model of frontotemporal dementia

 

2007 David Vocadlo

 

Simon Fraser University

 

Optimization of Pharmacokinetic and Pharmacodynamic Properties of a Small Molecule O-glycosylation Inhibitor for Treatment of Frontotemporal Dementia

 

Postdoctoral Fellow Awards

2013 M. Catarina Silva Harvard University Chemical neurobiology of tauopathy patient iPSC-derived neurons
2011 Alexandra Nicholson Mayo Clinic-Jacksonville TMEM106B and related family members in progranulin biology
2009 Todd Cohen University of Pennsylvania TDP-43 Acetylation and its Link to Frontotemporal Dementia